Conference Day One

Wednesday September 10, 2025

8:00 am Registration, Light Breakfast & Networking

8:50 am Chair’s Opening Remarks

Embracing the Application of Digital Pathology for Antibody-Drug-Conjugates (ADCs) to Optimize Therapeutic Effect

9:00 am Enhancing ADC Patient Selection Through Digitally Quantified Biomarkers & Morphology

  • Robin Edwards Vice President - Translational Medicine, MacroGenics

Synopsis

  • Describe how digital pathology may improve the quantification of biomarkers to more accurately identify patients most likely to benefit from ADC therapies
  • Define tumor morphologic features, tumor cell and TME-related, that should be assessed as the field works to expand its understanding of predictive biomarkers for ADC therapies
  • Discuss how AI-driven image analysis may support more nuanced stratification in tumors with heterogeneous target expression

9:30 am Session Details to be Confirmed

10:00 am Speed Networking Break & Morning Refreshments

Synopsis

Kick off your summit experience by building valuable new connections across the digital pathology and AI community. This interactive session is designed to ensure all attendees have the chance to quickly meet peers facing similar challenges and opportunities, helping you spark conversations that last well beyond the summit.

The Next Frontier: Leveraging AI & Spatial Biology to Unlock Unprecedented Insights into Disease Populations

11:00 am Integrating Image Analysis & Spatial Technologies to Advance Quantitative Biomarker Discovery in Preclinical Studies

Synopsis

  • Showcasing workflows to automate H&E and IHC image analysis for improved biomarker quantitation in rodent and human tissues
  • Exploring the integration of spatial proteomics and transcriptomics to enhance biomarker validation and tissue segmentation
  • Sharing key challenges, practical lessons, and future opportunities for applying spatial image analysis in preclinical drug discovery

11:30 am Integrating AI-Powered Algorithms into Digital Pathology Workflows to Advance Preclinical Decision-Making & Toxicological Insights

  • Xavier Palazzi Vice President & Head of Global Pathology, AstraZeneca

Synopsis

  • Exploring how AI-powered tools are being embedded into digital pathology workflows to support faster, more consistent decision-making in preclinical research
  • Highlighting strategies to improve the detection of tissue abnormalities and enhance pathology assessments through AI-driven insights
  • Discussing the broader potential of AI integration to elevate translational research, accelerate drug development, and support regulatory readiness

12:00 pm Lunch Break & Networking

Driving Confidence Through Rigorous Validation of Technologies to Boost Clinical Adoption of Digital Pathology

1:00 pm Understanding Pathologist Variability Helps Define Endpoints & Support Digital Pathology Processes In Celiac Disease

  • Joseph Maxwell Director - Early Clinical Development, Translational Biomarker GI-TAU Lead, Takeda Pharmaceutical

Synopsis

  • Celiac disease clinical trials are expected by regulators to show changes in histology endpoints
  • Digital pathology makes measurement and storage of data much easier but still requires clear alignment among pathologists for how their measurements will be done
  • Application of feedback from pathologists can support improvements in the digital pathology process for late stage clinical trials and provide a grounding point for automation

1:30 pm
Session Reserved for BioIVT

1:40 pm Panel Discussion: Ensuring High-Quality, Diverse Data Inputs & Regulatory Alignment for Robust AI in Digital Pathology

  • Jimena Trillo Tinoco Director, Translational Pathology, Daiichi Sankyo
  • Javier Perez Senior Director, Precision Medicine Dx Digital Pathology Strategy Oncology (DP & Ai), Regeneron Pharmaceuticals
  • Daryl Waggott Director, Biologics Data Products, BioIVT

Synopsis

  • How do quality and diversity of biospecimens directly impact the robustness, reproducibility, and clinical relevance of AI models in digital pathology?
  • How can the industry navigate evolving regulatory requirements around data quality, consent, and diversity to ensure AI tools meet compliance and accelerate approvals?
  • How can trusted data partnerships help build sustainable reference sets and enable continuous validation to future-proof AI and digital pathology solutions?

2:30 pm Afternoon Networking Break & Scientific Poster Session

Synopsis

Contribute to the conversation and share your cutting-edge research with your fellow digital pathology and AI community to showcase your breakthrough discoveries to a vast audience of experts.

Register your place to submit an abstract for review to showcase your poster, for more information get in touch at info@hansonwade.com.

Forging Strategic Partnerships as Catalysts for Scaling Digital Pathology in Clinical Trials & Creating Long-Term Value

3:30 pm Deep Dive Commercialization Session: Commercial Considerations for Digital Pathology Assets Supporting Therapeutics

  • Kristine Garside Director, Digital Health, Global Commercial Strategy Organization, Johnson & Johnson
  • Ralph Riley Director - Precision Medicine Access & Policy Strategy, Johnson & Johnson

Synopsis

While the promise of digital pathology is clear, clinical adoption at scale is still out of reach. This workshop will explore the commercial realities of deploying digital pathology tools beyond clinical trials, examining where value is created, who benefits, and how success is measured.

  • Advancing this field starts with asking the right questions
  • Join this workshop to:
  • Craft a solution that meets real commercial needs and drives market success
  • Unlock powerful insights by engaging the right stakeholders from the start
  • Redefine value by embracing solutions that break away from traditional expectations and deliver unexpected impact

4:50 pm Chair’s Closing Remarks

5:00 pm End of Conference Day One